Coronado looks at ophthalmic acquisitions:
This article was originally published in Clinica
US ophthalmic company Coronado Industries is looking at various medical product lines for acquisition to assist in its revenue stream pending FDA approval for its pneumatic glaucoma treatment device. The company is already selling its low cost pneumatic trabeculoplasty (PNT) device in Europe, through its wholly owned subsidiaries, American Glaucoma and Ophthalmic International. It claims that PNT is a non-invasive cost-effective procedure compared to traditional treatments. Coronado, of Fountain Hills, Arizona will license the device in the US upon FDA approval.
You may also be interested in...
Will the second wave of coronavirus lockdown have the same impact on the European consumer health industry? Speaking exclusively to HBW Insight from Germany, Merz Consumer Care CEO Frank Baldauf thinks not. Recently investing in premium beard care brand Brooklyn Soap and launching its tetesept Formula range in the Netherlands, Merz's Baldauf suggest that there will be less panic buying this time round and the CHC supply chain will hold up under pressure.
After a strong first quarter, Japan’s Towa Pharmaceuticals saw stability in its domestic revenues but a drop in revenues from its overseas business in its financial second quarter. After launching a series of molecules in June 2020, the company has lined up 10 launches for December 2020 as well.
Pfizer has revealed launch plans for its Nyvepria pegfilgrastim biosimilar, shortly after receiving formal European Commission approval.